The Life Sciences team advised Sionna Therapeutics on the closing of its $182 million Series C financing round. The round was led by Enavate Sciences, which invests in and supports the strategic growth of innovative therapeutic and enabling technology companies that have the potential to transform patient care and improve quality of life, with additional participation from existing investors including OrbiMed, Atlas Venture, RA Capital, The Rise Fund Sling (TPG), the Cystic Fibrosis Foundation, T. Rowe Price, and the Qatar Investment Authority, and new investors Perceptive Advisors and Viking Global Investors.
Sionna is a clinical-stage life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis by normalizing the function of CFTR, the key protein associated with disease progression in cystic fibrosis.
The deal team was led by Gaby Morales-Rivera and included Catherine Magazu, Jake Hays, Sumin Seo, Jimmy Bromley, Mark Burnett, Noelle Dubiansky, Xiaowei Wu, Steven Tjoe, Jacqueline Klosek, Ce Li, Gozde Guckaya, Daniel Karelitz and Emily Unger, with invaluable assistance from Megan Meyer. Sionna is a client of Bill Collins.
For additional details on the financing round, please read the press release.